Hyderabad, India and Princeton, NJ, USA. July 18, 2016—Dr. Reddy’s Laboratories Ltd (BSE: 500124,
NSE: DRREDDY, NYSE: RDY) announced today that it has launched Omeprazole and Sodium
bicarbonate capsules, 20mg/1100mg and 40mg/1100mg, a therapeutic equivalent generic version of
ZEGERID®(omeprazole/sodium bicarbonate) capsules in the United States market, having been approved by the U.S. Food & Drug Administration (USFDA).
The Zegerid®brand and generic had U.S. sales of approximately $306.7 million MAT for the most recent twelve months ending in May 2016 according to IMS Health*.
Dr. Reddy’s Omeprazole and sodium bicarbonate capsules 20 mg/1100 mg and 40 mg/1100 mg are
available in bottle count size of 30.
Zegerid® is a registered trademark of Santarus, Inc. a wholly owned subsidiary of Salix Pharmaceuticals,
Inc.
NSE: DRREDDY, NYSE: RDY) announced today that it has launched Omeprazole and Sodium
bicarbonate capsules, 20mg/1100mg and 40mg/1100mg, a therapeutic equivalent generic version of
ZEGERID®(omeprazole/sodium bicarbonate) capsules in the United States market, having been approved by the U.S. Food & Drug Administration (USFDA).
The Zegerid®brand and generic had U.S. sales of approximately $306.7 million MAT for the most recent twelve months ending in May 2016 according to IMS Health*.
Dr. Reddy’s Omeprazole and sodium bicarbonate capsules 20 mg/1100 mg and 40 mg/1100 mg are
available in bottle count size of 30.
Zegerid® is a registered trademark of Santarus, Inc. a wholly owned subsidiary of Salix Pharmaceuticals,
Inc.